ESR1 and breast carcinoma: The primary purpose of anti-hormone therapy is to prevent E2 from binding to ERα (SERMs) or inhibit synthesis of E2 (AIs) in ER-positive breast cancer, thereby blocking the proliferation of breast cancer cells.